Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
- Market Cap ₹ 32,977 Cr.
- Current Price ₹ 1,947
- High / Low ₹ 2,650 / 1,227
- Stock P/E 51.4
- Book Value ₹ 90.9
- Dividend Yield 1.64 %
- ROCE 36.4 %
- ROE 26.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 46.4%
- Company has been maintaining a healthy dividend payout of 107%
Cons
- Stock is trading at 21.4 times its book value
- The company has delivered a poor sales growth of 2.52% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,414 | 2,647 | 2,563 | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,311 | |
1,612 | 1,824 | 2,034 | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,490 | |
Operating Profit | 802 | 822 | 528 | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 821 |
OPM % | 33% | 31% | 21% | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 25% |
-177 | 30 | 203 | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -15 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 |
Depreciation | 20 | 18 | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 69 |
Profit before tax | 605 | 834 | 711 | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 736 |
Tax % | 29% | 33% | 32% | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | |
429 | 562 | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 529 | |
EPS in Rs | 25.30 | 33.17 | 28.43 | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 31.23 |
Dividend Payout % | 89% | 75% | 88% | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 3% |
3 Years: | 0% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | -1% |
5 Years: | 12% |
3 Years: | 44% |
TTM: | 47% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 8% |
3 Years: | 11% |
1 Year: | 53% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 34% |
3 Years: | 46% |
Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 |
Reserves | 1,851 | 1,922 | 1,905 | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,370 |
5 | 5 | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 21 | |
1,089 | 1,077 | 1,136 | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,312 | 1,602 | 1,950 | 1,570 | 1,709 | |
Total Liabilities | 3,030 | 3,088 | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,270 |
99 | 89 | 100 | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 318 | |
CWIP | 16 | 44 | 62 | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 26 |
Investments | 112 | 55 | 10 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 514 |
2,802 | 2,900 | 2,958 | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,255 | 2,715 | 3,907 | 2,458 | 2,412 | |
Total Assets | 3,030 | 3,088 | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,270 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
335 | 314 | 281 | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | |
358 | -110 | 189 | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | |
-395 | -441 | -494 | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | |
Net Cash Flow | 299 | -237 | -24 | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 13 | 16 | 14 | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 |
Inventory Days | 132 | 94 | 109 | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 |
Days Payable | 80 | 78 | 90 | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 |
Cash Conversion Cycle | 66 | 32 | 33 | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 |
Working Capital Days | -49 | -42 | -45 | -48 | 26 | 7 | -90 | -72 | -38 | -37 | -92 | -55 |
ROCE % | 48% | 50% | 34% | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Closure of Trading Window 2d
- Disclosure Under Clause 30 22 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 6 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
Concalls
-
Feb 2024Transcript PPT
-
Mar 2023TranscriptPPT
-
Aug 2022Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.